U.S. Food and Drug Administration Approves Opdivo® (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung CancerBusiness Wire • 03/04/22
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender OffersBusiness Wire • 03/02/22
Bristol Myers Squibb Announces Early Participation Results, Upsizing and Early Settlement of Tender OffersBusiness Wire • 03/02/22
Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers SquibbPRNewsWire • 03/01/22
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung CancerBusiness Wire • 02/28/22
Here's Why Bristol Myers Squibb Stock Is A Better Pick Over This Pharmaceutical BellwetherForbes • 02/25/22
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1.Business Wire • 02/25/22
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma.Business Wire • 02/25/22
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%Business Wire • 02/25/22
Bristol Myers Shares Interim Data From Long-Term Study Of Zeposia In Ulcerative ColitisBenzinga • 02/17/22
Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative ColitisBusiness Wire • 02/17/22
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell LymphomaBusiness Wire • 02/17/22
Bristol Myers Squibb: Bull Thesis Supported By Both Strong Technical And Fundamental SignalsSeeking Alpha • 02/17/22
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction TherapyBusiness Wire • 02/16/22
Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer TrialBenzinga • 02/15/22
Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 BillionBusiness Wire • 02/15/22
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell CarcinomaBusiness Wire • 02/14/22
